STAGE IIIB BLADDER CANCER AJCC V8
Clinical trials for STAGE IIIB BLADDER CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IIIB BLADDER CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IIIB BLADDER CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo targets tough bladder cancers
Disease control OngoingThis early-stage trial tests a combination of two drugs—erdafitinib and enfortumab vedotin—for people with advanced bladder cancer that has spread and has specific FGFR2/3 gene changes. The goal is to find the safest and most effective dose and see if the combo can shrink or stab…
Matched conditions: STAGE IIIB BLADDER CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 07:18 UTC
-
New combo aims to tame Immunotherapy's side effects in advanced cancers
Disease control OngoingThis study tests whether adding tocilizumab to standard immunotherapy (ipilimumab and nivolumab) can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive the combination to see if it is safer and still eff…
Matched conditions: STAGE IIIB BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
Can your genes tell if immunotherapy will work? new study investigates
Knowledge-focused OngoingThis study looks at whether specific gene mutations (ARID1A and KDM6A) and a protein called CXCL13 can predict how well the immunotherapy drug nivolumab works in people with advanced bladder cancer that has spread. About 6 participants with these gene changes will receive nivolum…
Matched conditions: STAGE IIIB BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated May 26, 2026 07:22 UTC